🇺🇸 FDA

Intelligence Platform

Patents

Browse 1,015 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11505594

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11498963

Anti-LILRB antibodies and their use in detecting and treating cancer

The Board of Regents of the University of Texas System · Granted Tue Nov 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11492392

Polynucleotides encoding anti-C5 antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11484591

Chemoprevention using controlled-release formulations of anti-interleukin 6 agents, synthe

THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Nov 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11485793

Anti-MUC16 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11485770

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11479602

Methods of treating C5-associated diseases comprising administering anti-C5 antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11471443

Anti-flavivirus compounds and methods of use

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Oct 18 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11472812

Anti-cancer compounds targeting Ral GTPases and methods of using the same

The Regents of the University of Colorado, a Body Corporate · Granted Tue Oct 18 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11464801

Compositions and methods for treating cancer with anti-CD33 immunotherapy

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Oct 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11459373

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11459374

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11459385

Anti-IL-2 antibodies and compositions and uses thereof

The Regents of the University of California · Granted Tue Oct 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11458107

Abiotic anti-VEGF nanoparticle

The Regents of the University of California · Granted Tue Oct 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11453721

Bispecific anti-MUC16 x anti-CD28 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 27 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11453719

Compositions and methods for treating cancer with anti-ROR1 immunotherapy

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Sep 27 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11446302

Compounds with anti-tumor activity against cancer cells bearing EGFR or HER2 exon 20 mutat

The Board of Regents of the University of Texas System · Granted Tue Sep 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11447541

Anti-coronavirus antibodies and methods of use

The United States of America, as represented by the Secretary, Department of Health and Human Svcs. · Granted Tue Sep 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11440950

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 13 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11440956

Anti-thyroglobulin T cell receptors

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Sep 13 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11439683

Anti-angiogenic therapy of metastatic colorectal cancer

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 13 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11434301

Anti-CD46 antibodies and methods of use

The Regents of the University of California · Granted Tue Sep 06 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11434304

Anti-CD38 antibodies

Takeda Pharmaceutical Company Limited · Granted Tue Sep 06 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11433013

Peptide for preventing skin damage caused by air pollutants and for anti-aging, and use th

CAREGEN CO., LTD. · Granted Tue Sep 06 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted